Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

Rhea-AI Summary

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announces the selection of interim efficacy and safety data from the Phase 2 TATCIST clinical trial for a poster presentation at the AACR Annual Meeting 2024, focusing on FPI-2265 in patients with mCRPC.

HAMILTON, ON and BOSTON, March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Presentation at AACR Annual Meeting 2024:

Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (²²⁵Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Session: Phase II Clinical Trials 1
Session Date and Time: Tuesday April 9, 2024, 9:00 a.m – 12:30 p.m. PT
Location: Poster Section 49
Abstract Number: CT224

The poster will be available on Fusion's website following the presentation. For more details about the AACR Annual Meeting, please visit: https://www.aacr.org/meeting/aacr-annual-meeting-2024/.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical-stage development portfolio includes lead program, FPI-2265, targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer currently in a Phase 2 trial and novel targeted alpha therapies (TATs) including next-generation antibody drug conjugates (ADCs). Fusion has a collaboration with AstraZeneca to jointly develop novel TATs and combination programs between Fusion's TATs and AstraZeneca's DNA damage response inhibitors and immuno-oncology agents. Fusion has a fully operational Good Manufacturing Practice compliant state-of-the-art radiopharmaceutical manufacturing facility to meet supply demand for  the Company's growing pipeline of TATs. The Company has strategic actinium supply agreements with Niowave, Inc. and BWXT Medical.

Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-interim-data-from-the-phase-2-tatcist-clinical-trial-evaluating-fpi-2265-at-the-2024-aacr-annual-meeting-302080615.html

SOURCE Fusion Pharmaceuticals

FAQ

What is the focus of Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) in the Phase 2 TATCIST clinical trial?

The focus is on evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC).

When and where will the poster presentation take place for the Phase 2 TATCIST clinical trial?

The poster presentation will be at the AACR Annual Meeting 2024 on Tuesday, April 9, 2024, from 9:00 a.m. to 12:30 p.m. PT in San Diego, California.

What is the title of the poster presentation for the Phase 2 TATCIST clinical trial?

The title is 'Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).'

Where can the poster be accessed after the presentation?

The poster will be available on Fusion's website after the presentation.